Book Chapter

Absence of tmRNA has a protective effect against fluoroquinolones in *Streptococcus pneumoniae*

Liliana Brito¹, Joana Wilton¹#, María José Ferrándiz², Alicia Gómez-Sanz¹, Adela G de la Campa²,³* and Mónica Amblar¹*

¹Unidad de Patología Molecular del Neumococo, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Spain
²Unidad de Genética Bacteriana, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Spain
³Presidencia, Consejo Superior de Investigaciones Científicas, Spain

#Gene Regulation / Microenvironments for New Therapies Lab, Instituto de Investigação e Inovação em Saúde; Universidade do Porto, Portugal

*Corresponding Authors: Adela G de la Campa, Unidad de Genética Bacteriana, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

Mónica Amblar, Unidad de Patología Molecular del Neumococo, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

Published October 26, 2020

This Book Chapter is a republication of an article published by Mónica Amblar, et al. at Frontiers in Microbiology in January 2017. (Brito L, Wilton J, Ferrándiz MJ, Gómez-Sanz A, de la Campa AG and Amblar M (2017) Absence of tmRNA Has a Protective Effect against Fluoroquinolones in *Streptococcus pneumoniae*. Front. Microbiol. 7:2164. doi: 10.3389/fmicb.2016.02164)
How to cite this book chapter: Liliana Brito, Joana Wilton, María José Ferrándiz, Alicia Gómez-Sanz, Adela G de la Campa, Mónica Amblar. Absence of tmRNA has a protective effect against fluoroquinolones in Streptococcus pneumoniae. In: Alexandre Morrot, editor. Prime Archives in Microbiology. Hyderabad, India: Vide Leaf. 2020.

© The Author(s) 2020. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author contribution: LB, JW, MJF, AGS and MA performed the experimental work. MA, AGC and MJF participated in study conception, data interpretation and manuscript writing. All authors participated in manuscript corrections.

Funding: This work was supported by the Fondo de Investigación Sanitaria (FIS) from Instituto de Salud Carlos III (PI11/00656) and Ministerio de Economía y Competitividad (BIO2014-55462-R). LB and JW were recipients of grants from the Inov Contacto C19 and 18 programs, respectively, attributed by the Agência para o Investimento e Comércio Externo de Portugal with Portuguese and European funds. AG was recipient of a contract funded by Instituto de Salud Carlos III (CA10/1103).

Acknowledgements: We thank C. Herranz for invaluable technical assistance. The work was performed under the auspices of the Instituto de Salud Carlos III.

Abstract

The transfer messenger RNA (tmRNA), encoded by the ssrA gene, is a small non-coding RNA involved in trans-translation that contributes to the recycling of ribosomes stalled on aberrant mRNAs. In most bacteria, its inactivation has been related to a decreased ability to respond to and recover from a variety of stress conditions. In this report, we investigated the role of
tmRNA in stress adaptation in the human pathogen *Streptococcus pneumoniae*. We constructed a tmRNA deletion mutant and analyzed its response to several lethal stresses. The ΔssrA strain grew slower than the wild type, indicating that, although not essential, tmRNA is important for normal pneumococcal growth. Moreover, deletion of tmRNA increased susceptibility to UV irradiation, to exogenous hydrogen peroxide and to antibiotics that inhibit protein synthesis and transcription. However, the ΔssrA strain was more resistant to fluoroquinolones, showing 2-fold higher MIC values and up to 1000-fold higher survival rates than the wild type. Deletion of SmpB, the other partner in trans-translation, also reduced survival to levofloxacin in a similar extent. Accumulation of intracellular reactive oxygen species associated to moxifloxacin and levofloxacin treatment was also highly reduced (~100-fold). Nevertheless, the ΔssrA strain showed higher intracellular accumulation of ethidium bromide and levofloxacin than the wild type, suggesting that tmRNA deficiency protects pneumococcal cells from fluoroquinolone-mediated killing. In fact, analysis of chromosome integrity revealed that deletion of tmRNA prevented the fragmentation of the chromosome associated to levofloxacin treatment. Moreover, such protective effect appears to relay mainly on inhibition of protein synthesis, since a similar effect was observed with antibiotics that inhibit that process. The emergence and spread of drug-resistant pneumococci is a matter of concern and these results contribute to a better comprehension of the mechanisms underlying fluoroquinolones action.

**Keywords**

*Streptococcus pneumoniae*; tmRNA; Trans-Translation; Stress Adaptation; Antibiotic Resistance; Fluoroquinolones; Chromosomal Fragmentation; Reactive Oxygen Species

**Introduction**

The transfer-messenger RNA (tmRNA) is a ubiquitous specialized small non-coding RNA encoded by the *ssrA* gene that functions as both a tRNA and an mRNA. It works together with the SmpB protein in the trans-translation system, a quality control
pathway that rescues ribosomes stalled on non-stop mRNAs [1-3]. During trans-translation, the tmRNA-SmpB complex shifts the translation of the nascent peptide from the aberrant mRNA to the tmRNA-coding sequence, allowing resumption of translation while targeting the peptide for degradation and recycling ribosomes [4,5]. Accumulation of stalled ribosomes is toxic and they need to be rescued, otherwise, the cell would rapidly be depleted of translational ribosomes and protein synthesis would come to halt. Some bacteria have alternative backup systems that use either ArfA or ArfB factors to recognize no-stop complexes, promote hydrolysis of the peptidyl-tRNA and release the stalled ribosome [6-9]. Impairment of trans-translation leads to a wide variety of phenotypes, likely influenced by the status of ArfA and/or ArfB. These phenotypes range from very subtle growth defects to lethality, but the most common are associated to defects in pathogenicity and stress-adaptation [10-20], or to increased sensitivity to antibiotics targeting translation [17,19-24]. In addition to quality control pathways, some genetic regulatory circuits use trans-translation to control gene expression, and diverse bacteria require trans-translation when they execute large changes in their genetic programs [25-31]. Therefore, the contribution of tmRNA and the trans-translation mechanism to cell survival differs among bacteria, and key questions regarding their utility remain unanswered.

We wanted to investigate the role of the tmRNA in the human pathogen *Streptococcus pneumoniae*. This bacterium is responsible for a wide spectrum of human diseases, ranging from mild otitis media to more severe infections such as meningitis, sepsis or endocarditis [32]. It is the most common bacterial cause of community-acquired pneumonia and the leading cause of vaccine-preventable deaths in children <5 years old [33] (www.who.int). Treatment of pneumococcal diseases is hampered by the emergence and spread of drug-resistant strains to traditionally effective agents, including beta-lactam antibiotics [34] and macrolides [35]. Fluoroquinolones (FQs), such as levofloxacin (LVX) and moxifloxacin (MOX), are currently used for the treatment of pneumococcal pneumonia in adult patients. These antibiotics inhibit type II DNA topoisomerases, ubiquitous enzymes that manage DNA topology and solve topological
problems associated with DNA replication, transcription, and recombination [36]. It has been proposed that several FQs require ongoing protein synthesis to cause cell death, and that protein synthesis inhibitors may protect from chromosome fragmentation [37-39]. In addition, reactive oxygen species (ROS) such as superoxide, hydrogen peroxide (H$_2$O$_2$) and hydroxyl radical, contribute to FQ-mediated killing [40-44]. In S. pneumoniae, the mechanisms leading to ROS accumulation mediated by LVX and MOX have been recently elucidated [45,46]. Both FQs induce global transcriptional responses that, although through different pathways, ultimately stimulate the Fenton reaction, increasing ROS accumulation and contributing to cell death.

Expression of tmRNA in the pneumococcus was recently demonstrated [14,47-49] and, although no functional studies have been reported so far, its deficiency has strong effects in pathogenesis. In fact, ssrA inactivation reduced the ability to adhere and to invade endothelial cells, reduced the fitness and competitive index in lungs and causes attenuation in invasive diseases upon intranasal challenge [14]. Regarding SmpB, its partner in trans-translation, it has been demonstrated that expression of the pneumococcal SmpB protein is induced under cold-shock and that its levels are regulated by RNase R, an exoribonuclease involved in degradation of faulty mRNAs released from stalled ribosomes during trans-translation [50,51]. However, a direct link between trans-translation and survival to stress or antibiotic susceptibility/resistance, have never been established in S. pneumoniae.

The aim of the present study was to investigate the role of tmRNA in adaptation of S. pneumoniae to environmental conditions and antibiotic stress. We examined how the absence of tmRNA affects survival to several lethal environmental conditions and the activity of chemically-unrelated antibiotics, some of which are commonly used in clinical practice. We showed that tmRNA deficiency had a detrimental effect on growth and was more sensitive to UV, H$_2$O$_2$ and to a variety of antibiotics. However, deletion of tmRNA highly increased bacterial survival against FQs, decreased accumulation of intracellular ROS and reduced chromosomal fragmentation. This
is the first study reporting a higher FQ-resistance phenotype associated to tmRNA deficiency, which has been generally considered as a stress-adaptation RNA.

**Materials and Methods**

**Bacterial Strains, Plasmids, Growth Conditions and Transformation**

*S. pneumoniae* strains and plasmids used in this study are described in Table 1. Pneumococci were grown as static cultures either in Todd-Hewitt medium supplemented with 0.5% of yeast extract (THY), or in a casein hydrolase-based medium (AGCH) supplemented with 0.3% sucrose and 0.2% of yeast extract (A+SY). All constructs and cloning experiments were carried out in the pneumococcal R6 strain. TIGR4 cells were transformed as previously described [47] and plated onto blood agar plates. R6 cells were transformed as described previously [52] and transformants were plated on A+SY media plates containing 1% agar. Incubations were performed at 37ºC in a 5% CO₂ atmosphere. The pROM plasmid was constructed by deleting the 173 bp fragment containing the maltose-inducible promoter (PM) of pLS1ROM [53]. For this purpose, the whole plasmid (excluding PM) was amplified through reverse PCR using pROM-F-Xba2 and pROM-R-Xba2 primers (Table 2). The fragment was then digested with *Xba*I and further ligated to obtain pROM. The pROM-TM plasmid was obtained by cloning a 531 bp chromosomal region containing the entire tmRNA encoding gene *ssrA* (including its own promoter) into pROM. This fragment was amplified by PCR from TIGR4 chromosomal DNA using Expand High Fidelity (Roche). Primers used were tmRNACj-F and tmRNACj-R (Table 2), which contained the *BamHI* and *HindIII* restriction sites, respectively. The PCR product was cloned into pROM vector making use of the *BamHI* and *HindIII* restriction sites, thus obtaining the pROM-TM plasmid, which was then transformed into R6 competent cells. Transformants were selected using 1 µg/ml of erythromycin and cloning was verified by DNA sequencing. Expression of tmRNA in trans was confirmed by Northern-blot as previously described [47].
Table 1: Bacterial strains and plasmids used in this study.

| Bacterial strain | Description | Source |
|------------------|-------------|--------|
| TIGR4            | Capsular type 4 clinical isolate strain TIGR4 | [75] |
| TIGR4ΔssrA       | TIGR4 ssrA::Km<sup>r</sup> | This study |
| TIGR4ΔsmpB       | TIGR4 smpB::Km<sup>r</sup> | [50] |
| R6               | Non-encapsulated strain derived from the capsular type 2 clinical isolate strain D39 | Laboratory collection |
| R6ΔssrA          | R6 ssrA::Km<sup>r</sup> | This study |
| R6ΔssrA(ROM)     | R6ΔssrA [pROM] | This study |
| R6ΔssrA(ssrA<sup>+</sup>) | R6ΔssrA [pROM-TM] | This study |

| Plasmids         | Description | Source |
|------------------|-------------|--------|
| pLS1ROM          |             | [53] |
| pROM             | pLS1ROM lacking PM promoter | This study |
| pROM-TM          | pROM containing tmRNA chromosomal fragment | This study |

Construction of Genetically-Modified Strains

The TIGR4 tmRNA deletion mutant (TIGR4ΔssrA) was constructed by insertion-deletion of a kanamycin resistance cassette (Km<sup>r</sup>) through allelic replacement mutagenesis [54]. For this purpose, three fragments were generated by PCR. Two of them contained the upstream and downstream tmRNA regions and were obtained using oligonucleotide pairs tmRNA-F/tmRNAKmUp-R and tmRNAKmDown-F/tmRNA-R, respectively (Table 2). The third fragment, containing Km<sup>r</sup>, was amplified from pR410 plasmid [55] using KmN-F and KmN-R primers (Table 2). Primers tmRNAKmUp-R and tmRNAKmDown-F partially overlapped with KmN-F and KmN-R, respectively, to allow further hybridization of up- and downstream fragments with the amplified Km<sup>r</sup> fragment. The three resulting PCR products were purified, mixed together, amplified using tmRNA-F and tmRNA-R primers, and used to transform strain TIGR4 (Figure 1A). Construction of the R6 tmRNA deletion strain (R6ΔssrA) was performed through amplification of a 3744 bp fragment encompassing tmRNA insertion/deletion from TIGR4ΔssrA chromosomal DNA using tmRNA-1 and tmRNA-2 primers (Table 2) and further transformation of R6. In both cases, transformants were selected.
with 250 µg/ml of Km, and confirmed by PCR amplification with external oligonucleotides tmRNA-1 and tmRNA-2 and DNA sequencing.

**Figure 1**: tmRNA deficiency is detrimental under certain stress conditions. (A) Inactivation of *ssrA* gene (black) by insertion/deletion of Km’ (light gray). Flanking ORFs (white) and tRNA gene (dark gray) are depicted. Promoters (curved arrows), terminators (stem-loop structures) and primers used (black arrows) are shown. (B) Growth curves of wild type TIGR4 (*wt*) strain and its tmRNA deletion mutant (*ΔssrA*) in THY broth at 37°C. (C) Survival of *wt* and *ΔssrA* upon treatment with 30 mM paraquat at the indicated times, after UV irradiation at the intensities indicated, or after 30 min of exposure to 20 mM of hydrogen peroxide. Survival was determined as described in Materials and Methods. Values (mean ±SD) are the average of at least three independent experiments and the means were statistically compared using Student’s t-test (*P < 0.05; **P < 0.01).
Table 2: List of primers used in this study.

| Primer          | Nucleotide sequence 5’ to 3’ | Description                                      |
|-----------------|-------------------------------|--------------------------------------------------|
| tmRNA-F         | TTCTGTGTCAAGGTAAAGTTC       | Up PCR fragment for \( \Delta ssrA \) construction |
| tmRNA-KmUp-R    | TTATCCATAAAAATCAACAGGATCATCATACCTAAAGATGAAAGCTATCT | Down PCR fragment for \( \Delta ssrA \) construction |
| tmRNA-R         | ACTGAATCACCTCCTGTTATCG      |                                                   |
| kmN-F           | CCGTTTGATTTTTTAATGATAA      | Km\(^2\) cassette for \( \Delta ssrA \) construction |
| KmN-R           | CATTGATACAAATTCTCGTA        |                                                   |
| pLSROM-F-Xba2   | CGTCTGCAAAATACTCTAGAGATGGATCAAG | For pROM construction                           |
| pLSROM-R-Xba2   | CTACACGAGACAGTCTAGAAAGTACAAAAACCTCCC |                                                   |
| tmRNACj-F       | CGCGGATCTCTCATTTAGGTATGTAATTTC | For ssrA cloning                                |
| tmRNACj-R       | GCGCAAGCTTGCTGGTGTGTTGACTCCC |                                                   |
| tmRNA-1         | AATTATGCTGCGCTCCAGAA        | For \( \Delta ssrA \) construction and DNA sequencing |
| tmRNA-2         | TTTCAAGACACGGCTGACA         |                                                   |

**Hydrogen Peroxidase and Paraquat Sensitivity Assays**

Hydrogen peroxidase sensitivity assays were performed essentially as described by Pericone et al. [56]. Briefly, bacteria were grown in THY broth until an absorbance at 600 nm (\(A_{600}\)) of 0.2 and diluted 2-fold in the same medium containing 40 mM \(H_2O_2\) (Sigma-Aldrich), resulting in an true exposure of 20 mM \(H_2O_2\). Bacteria were incubated at 37ºC for 30 min and reactions were stopped by adding 200 U of bovine liver catalase (Sigma-Aldrich). Serial dilutions were plated in blood agar plates and incubated overnight at 37ºC in a 5% CO\(_2\) atmosphere. Percentage of survival cells was calculated relative to the untreated control bacteria. Paraquat sensitivity assays were performed as previously described [57]. Bacteria were grown until \(A_{600}=0.2\), and diluted 2-fold in the same medium with 30 mM paraquat (Sigma-Aldrich) or without paraquat, and incubated at 37ºC for 2-h. Samples were taken at time intervals and the number of viable cells was determined by plating onto blood agar plates.
Susceptibility to UV Irradiation Assays

Susceptibility to UV irradiation assays were performed as previously described [58]. Cells were grown in A+SY medium to exponential phase (an $A_{620}$ of approximately 0.2). Serial dilutions were then plated and exposed to UV light at 254 nm at the indicated intensities. Percentage of survival was estimated by colony counting relative to untreated control samples.

Antibiotic Susceptibility Studies and Detection of Reactive Oxygen Species

MICs were determined by the broth macrodilution method [59]. To measure lethal action of antibiotics, pneumococci were grown in A+SY medium to $A_{620}=0.4$, diluted 100-fold and treated with the antibiotic. Samples were withdrawn at time intervals and colony formation was determined by plating on drug-free blood agar plates. The percentage of surviving cells was calculated relative to untreated control samples. When indicated, 10 µg/ ml of chloramphenicol or 0.3 µg/ ml of erythromycin was added to the culture 10 min prior to FQ addition and maintained throughout treatment. Intracellular oxidation level upon FQ treatment was measured by ROS detection using dihydorhodamine 123 dye (Sigma-Aldrich) as previously described [45]. Results were expressed as relative fluorescence units (RFU) and were made relative to time point zero, and normalized according to the number of live cells at each time point.

Ethidium Bromide Uptake and Efflux Studies

Uptake of ethidium bromide (EtBr) was measured by fluorescence spectrophotometry as previously described [60] with several modifications. Bacteria were grown at 37ºC to mid-logarithmic phase ($A_{620}=0.4$) in A+SY medium. Cells were harvested, washed and suspended in phosphate saline buffer (PBS) (pH 7.2) with 0.2% glucose to $A_{620}=0.2$. After 10 min of incubation at 37ºC, bacteria were exposed to 2 µg/ ml of EtBr, with or without 20 µg/ ml reserpine. Increase of fluorescence as EtBr entered the cells was directly recorded along 20 min,
measuring every 0.25 seconds at 530 nm (excitation wavelength) and 600 nm (emission wavelength) in a Varian Cary Eclipse Spectrophotometer (Agilent Technologies Spain S.L. Madrid, Spain). The mean of at least three independent experiments was obtained.

Measurement of EtBr efflux was based on previously described method [61]. Bacterial suspensions at $A_{620}=0.2$ were prepared in PBS with 0.2% glucose as described above. Bacteria were then exposed to EtBr for 20 min at 37°C in the presence of reserpine to maximize EtBr loading into bacteria. Cells were collected by centrifugation and suspended in fresh PBS + 0.2% glucose. Efflux of EtBr from cells was measured as fluorescence signal decrease during 20 min.

**FQ Accumulation Measurements**

Accumulation of LVX on each strain was measured by fluorescence essentially as previously described [62]. A starter culture was diluted 40-fold in 100 ml of A+SY medium, and grown at 37°C to $A_{620}=0.5$. Cells were washed and concentrated 20-fold in 0.1 M sodium phosphate pH 7.0, and the suspension was equilibrated for 10 min at 37°C prior to accumulation measurements. LVX was added at different concentrations and suspensions were incubated at 37°C for the indicated times. 0.5 ml aliquots were withdrawn and added to 2.5 ml of ice-cold 0.1 M sodium phosphate, washed with the same buffer and resuspended in 0.1 M glycine pH 3 to achieve cell lysis. After incubating at room temperature overnight, samples were centrifuged twice at 10000 x g for 10 min. LVX concentration in the supernatant was measured by fluorescence spectroscopy at 295 nm (excitation wavelength) and 496 nm (emission wavelength), and compared to a standard fluorescence curve previously obtained. Accumulation data were converted into µg of LVX per ml.

**Analysis of Chromosome Fragmentation by PFGE**

Chromosomal fragmentation was detected by pulsed-field gel electrophoresis (PFGE) as previously described [46]. A starter
culture was diluted 40-fold in A+SY medium and grown at 37°C to $A_{620}=0.3$. Bacteria were then treated with 10× MIC of LVX and incubated at 37°C for an additional 30 min. Cells were harvested, washed twice with wash buffer (1M NaCl, 10 mM Tris pH 8) and inserted in solid agarose blocks for further lysis as described previously [46]. Electrophoresis was performed in a Cheff-DR III system (Bio-Rad), for 20 h at 5.8 V/cm with a 0.1- to 40-s switch-time ramp at 14°C. Gels were stained with 0.5µg/ml EtBr for 1h and further distained in water during the same time. Percentages of chromosomal fragmentation were estimated by quantification of relative band intensities in each lane, corresponding to fragmented (compression zone) and non-fragmented (retained in the well) DNA.

**Results**

**Deficiency of tmRNA Reduces Bacterial Growth and Increases Sensitivity to Stress**

tmRNA is a major actor in the trans-translation mechanism and, although its contribution to cell survival differs among bacteria, its inactivation is expected to diminish recovery from stress. To investigate the role of tmRNA in *S. pneumoniae* we constructed a TIGR4 tmRNA mutant (TIGR4ΔssrA) by deletion of its ssrA encoding gene and insertion of Km (Figure 1A). Deletion of ssrA increased the doubling time at 37°C from 42.8 min ± 1.9 (mean ± SD) to ~ 61.7 min ± 2.4 (Table 3). These results indicated that, although tmRNA is not essential for the pneumococcus, its absence has a detrimental effect on growth (Figure 1B). We next evaluated the sensitivity to various environmental stress conditions. TIGR4ΔssrA was 3 to 4-fold more susceptible than TIGR4 to 30 mM paraquat, which induces formation of superoxide inside the cell (Figure 1C). However, these differences, although evident, were not statistically significant ($P = 0.055$ after 60 min and $P = 0.092$ after 120 min). By contrast, TIGR4ΔssrA was significantly more susceptible to treatment with UV light at 254 nm, with survival rates 2.5-fold (at 10 J x m$^{-2}$; $P = 0.015$) and 3-fold (at 20 J x m$^{-2}$; $P = 0.0027$) lower than TIGR4 (Figure 1C). Moreover, addition of exogenous H$_2$O$_2$ was highly deleterious for TIGR4ΔssrA, whose survival was reduced ~400-
fold after 30 min of incubation with 20 mM H$_2$O$_2$ ($P = 0.005$). These results revealed the importance of tmRNA and the trans-
translation mechanism in adaptation of *S. pneumoniae* to certain environmental stress conditions.

**Table 3:** Doubling time of pneumococcal strains used.

| Strain         | Duplication time (min) |
|----------------|------------------------|
|                | 37°C        | 30°C      |
| TIGR4          | 42.8 ± 1.9  | n.d.      |
| TIGR4ΔssrA     | 61.7 ± 2.4  | n.d.      |
| R6             | 48.6 ± 0.9  | 65.4 ± 1.0|
| R6ΔssrA        | 62.2 ± 2.2  | 95.7 ± 4.5|
| R6ΔssrA(ROM)   | 85.4 ± 5.6  | 108.1 ± 10.1|
| R6ΔssrA(sshA+) | 41.0 ± 2.4  | 68.6 ± 1.5|

$^1$ Values were calculated from growth curves performed in A+SY medium at 37 or 30°C in a TECAN infinite F200 plate reader and are the average ± standard deviation of, at least, three independent experiments. n.d., not determined.

We then examined the effect of the ssrA deletion under antimicrobial stress and determined the MIC values of several drugs from different families (Table 4). Deletion of ssrA lowered the MICs of antibiotics targeting translation, such as chloramphenicol (CM), erythromycin (EM) and tetracycline, and transcription, such as rifampicin, 2- or 4-fold, but had no effect with beta-lactams such as penicillin or cefotaxime, which interfere with cell wall synthesis. However, the MICs of MOX and LVX were higher for the ΔssrA strain than for the wild type by 1 dilution factor (Table 4). Such difference, although low, suggested that the tmRNA deletion reduces susceptibility to these drugs.
Table 4: *In vitro* antibiotic susceptibilities determined by macrodilution in TIGR4 and R6 strains of *S. pneumoniae*.

| Drug             | MIC µg/mL | TIGR4 | TIGR4ΔssrA | R6     | R6ΔssrA | Fold change  |
|------------------|-----------|-------|------------|--------|---------|--------------|
| Chloramphenicol  | 1         | 0.5   | n.d.       | n.d.   | 2 ↓     |
| Tetracycline     | 0.125     | 0.062 | n.d.       | n.d.   | 2 ↓     |
| Erythromycin     | 0.03      | 0.0075| n.d.       | n.d.   | 4 ↓     |
| Rifampicin       | 0.06      | 0.03  | n.d.       | n.d.   | 2 ↓     |
| Penicillin       | 0.016     | 0.016 | n.d.       | n.d.   |         |
| Cefotaxime       | 0.015     | 0.015 | n.d.       | n.d.   |         |
| Moxifloxacin     | 0.25      | 0.50  | 0.125      | 0.25   | 2 ↑     |
| Levofloxacin     | 0.50      | 1     | 0.25       | 0.50   | 2 ↑     |
| Ciprofloxacin    | n.d.      | n.d.  | 0.50       | 1      | 2 ↑     |
| Norfloxacin      | n.d.      | n.d.  | 4          | 8      | 2 ↑     |

1 Results are the average of at least three independent replicates. n.d., not determined. 2 Fold change denotes the ration between the values for the wild type strains and their corresponding ΔssrA derivative.

**Absence of tmRNA Increases Resistance to FQs and Reduces ROS Production**

To confirm the apparent lower susceptibility of ΔssrA and better understand the effect of tmRNA on FQ activity, we determined the survival of wild type and mutant strains upon treatment with different concentrations of LVX and MOX from 1 to 4 hours. The TIGR4ΔssrA was much more resistant to killing by both FQs at all times and concentrations tested, showing up to ~150- (for LVX) and ~100-fold (for MOX) higher survival rates than the wild type (Figure 2A). This effect was specific to FQs as no differences in survival were observed with the other bactericidal agent penicillin (Figure 2A). Moreover, this phenotype was associated to defects in trans-translation since similar survival rates to 5× MIC of LVX were observed with the ΔsmpB mutant lacking SmpB, the other indispensable partner for trans-translation (Figure 2A). Provided that FQ lethality is associated to ROS production, we determined the internal levels of ROS in TIGR4 and TIGR4ΔssrA upon LVX and MOX treatment at the same time points and antibiotic concentrations. ROS
accumulation in TIGR4ΔsrrA was highly reduced compared to TIGR4, showing a decrease of more than ~120-fold after 2 h treatment with both antibiotics (Figure 2B). These results demonstrated that the higher survival rate exhibited by TIGR4ΔsrrA is related with a reduction in ROS production.

**Figure 2**: Deletion of tmRNA reduces lethality of FQs but not of penicillin. (A) Percentage of survival of wt, ΔsrrA and TIGR4ΔsmpB (ΔsmpB) strains upon treatment with LVX, MOX and/or penicillin (PEN). Exponentially growing cells were treated with each antibiotic at the concentration and times indicated. Survival was determined as described in Materials and Methods. (B) Accumulation of ROS in wt and ΔsrrA strains upon treatment with 2.5 and 5× MIC of LVX and MOX were measured in the same samples as described in Materials and Methods. RFU, relative fluorescence units; fluorescence units were divided by the number of viable cells and normalized to time zero and no antibiotic treatment condition. Values (mean ±SD) of at least three independent experiments are shown. The MIC values used were those determined in Table 4.
To ensure that the less FQ-sensitive phenotype of the tmRNA deficiency was not related with the genetic background, a similar analysis was performed using strain R6. We constructed the R6ΔssrA strain and analyzed growth under different concentrations of LVX. As shown in Figure 3A, growth inhibition upon antibiotic treatment was lower in R6ΔssrA than in R6, and the differences between strains increased proportionally with LVX concentration up to 1 µg/ml. The study was extended to other FQs and the MIC values of LVX, MOX, ciprofloxacin (CPX) and norfloxacin (NFX) were determined. In all cases, the MICs were higher for R6ΔssrA than for R6 (Table 4), confirming less susceptibility to all FQs. We then compared survival of R6 and R6ΔssrA strains upon treatment with the four distinct FQs (Figure 3B). As in the TIGR4 genetic background, the lethal action of the four FQs was reduced several hundred-fold in the R6ΔssrA, and this effect was associated with >2-log decrease in ROS accumulation after LVX treatment (Figure 3C). To attribute protection from FQ lethal activity to tmRNA deficiency, complementation experiments were performed. The pROM-TM plasmid containing the entire ssrA gene was constructed and introduced into R6ΔssrA. Expression of tmRNA in trans in this strain was confirmed by Northern blot-analysis (Figure 3D). Survival during LVX treatment revealed that the complemented strain was killed to the same extent as R6, while R6ΔssrA with the empty vector did not (Figure 3B). Furthermore, since the potency of bactericidal compounds may increase with faster bacterial growth rate [63], the possibility exists that the higher survival to FQs shown by R6ΔssrA resulted from its slower growth. To exclude this possibility, we analyzed survival of R6 to LVX at 30°C, which reduced the doubling time of wild type cells (65.4 min ± 1.0) to the same levels as the R6ΔssrA mutant at 37°C (62.2 min ± 2.2) (Table 3). Results showed that resistance to LVX of R6 indeed partially increased at 30°C, showing 7.7- and 8.4-fold higher percentages of survival than at 37°C after 3h and 4h treatment, respectively (Figure 3B). However, these values were far from those obtained with R6ΔssrA at 37°C, which showed survival percentages of about 1100- and 450-fold higher after 3h and 4h of LVX-treatment, respectively.
Figure 3: tmRNA deficiency protects from FQs lethal action. (A) Wild type R6 strain (wt) and its tmRNA deletion mutant (ΔssrA) were grown under different LVX concentrations in A+Y medium. Growth was followed by turbidity (OD$_{620}$ nm) in a TECAN infinite F200 plate reader at 37 ºC. (B) Percentage of survival to different FQs of wt, ΔssrA, the complemented strain containing the pROM-TM (ΔssrA(ssrA$^+$)) and the ΔssrA containing the empty vector (ROM) at 37ºC, and of wt at 30ºC. Exponentially growing cells were treated with 5× MIC (as determined in Table 4) of LVX, ciprofloxacin (CPX), norfloxacin (NFX), or MOX for the times indicated. After incubation, survival was determined as described in Materials and methods. (C) Accumulation of ROS in wt and ΔssrA upon addition of 5× MIC of LVX was measured as described in Materials and methods. RFU; fluorescence units were divided by the number of viable cells and normalized to time zero and no antibiotic treatment condition. (D) Northern-blot showing tmRNA expression in wt, ΔssrA and ΔssrA(ssrA$^+$). Bands corresponding to tmRNA and the control 5S rRNA are indicated by arrows. Northern-blot results were performed as described (Acebo et al., 2012). Values (mean ±SD) of at least three independent experiments are shown. MIC values were determined in Table 4.
From these experiments we can conclude that $\Delta ssrA$ strain is better able to survive to the lethal effect of FQs than $ssrA^+$ cells and that this phenotype does not relay only in growth defect, but in another mechanism of protection directly linked with defects in trans-translation.

**tmRNA Deficiency Increases FQ Accumulation**

The less sensitive phenotype of the tmRNA deletion mutant could be due to a lesser accumulation of FQs inside the cell, due to changes in membrane permeability. To explore this possibility, we conducted experiments comparing EtBr uptake and efflux in both R6 and R6$\Delta ssrA$ strains. Results revealed that EtBr uptake was higher in R6$\Delta ssrA$ than in R6 and, simultaneously, the efflux was lower (Figure 4A). As a consequence, internal levels of EtBr in R6$\Delta ssrA$ were higher than in R6. Addition of reserpine, an efflux pump inhibitor in streptococci [62,64], considerably increased EtBr accumulation in the wild type strain, while the effect in R6$\Delta ssrA$ was much lower. Remarkably, EtBr levels accumulated in R6 upon reserpine addition were equivalent to the levels in R6$\Delta ssrA$ without the inhibitor. These results indicate that the efflux pumps in R6$\Delta ssrA$ are less active in exporting EtBr, leading to higher accumulation of this drug. We analyzed whether the observed effect was specific to EtBr or whether the accumulation of LVX was also increased in the $\Delta ssrA$ mutant. We examined levels of intracellular LVX upon treatment with different antibiotic concentrations and different exposure times. Again, R6$\Delta ssrA$ accumulated higher amounts of LVX than R6 in all cases (Figure 4B). These results suggest that the absence of tmRNA indeed induces changes in *S. pneumoniae* membrane permeability. However, instead of reducing levels of EtBr and LVX inside the cell, these changes lead to their higher accumulation.
Figure 4: tmRNA deficiency leads to higher intracellular accumulation of drugs. (A) EtBr uptake (left panel) and efflux (right panel) of R6 (wt) and R6ΔssrA (ΔssrA) strains during 20 min was measured as described in Materials and methods. Fluorescence intensity represents levels of intracellular EtBr. The change in fluorescence is normalized to the initial levels to allow for direct comparison. Fluorescence was directly recorded during 20 min after addition of EtBr in the presence (+Res) or in the absence of reserpine. (B) Fluorometric measurement of intracellular accumulation of levofloxacin (LVX) in wt and ΔssrA at different LVX concentrations (left panel) and time points (right panel), as described in Materials and Methods. Three to five independent experiments were conducted and the mean values were statistically compared using Student’s t-test (*P < 0.05).
Absence of tmRNA Protects from Chromosomal Fragmentation Associated to FQs

Since the lethal effect of FQs has been correlated with chromosome fragmentation, we examined LVX-associated DNA breakage in R6 and R6ΔssrA after 30 min of exposure to 10× MIC of LVX (Figure 4). Percentage of the bands corresponding to the compression zone (CZ, containing the large size nicked fragments of chromosomal DNA) was used to estimate chromosomal fragmentation. As shown in Figure 5A and B, LVX treatment induced a 16.7% ± 1.6 (mean ± SD) fragmentation in R6, compared with the 6.5% ± 1.9 observed without the antibiotic. However, such increase was not observed in R6ΔssrA, whose fragmentation levels with and without LVX were similar (7.1% ± 1.25 and 6.7% ± 2.6, respectively). Interestingly, overexpression of tmRNA in the complemented strain completely restored the initial levels of fragmentation to 16.5% ± 2.7, while the empty vector did not (8.8% ± 2.2). Therefore, we can conclude that the absence of tmRNA protects from chromosome fragmentation associated to FQs treatment.

Absence of tmRNA is expected to slow down translation due to lack of turnover of stalled ribosomes and it is known that in E. coli several FQs require active protein synthesis to cause cell death [38,39]. Therefore, it is possible that the protective effect of ΔssrA could be related to a lower protein synthesis rate. To explore this possibility, we tested the effect of the protein inhibitor CM as a blocking agent of FQ-lethal action in the pneumococcus. For this purpose, bacterial cultures were treated with 10× MIC of CM for 10 min, and then different concentrations of LVX were added for 1 additional hour. As shown in Figure 5C, incubation with CM drastically reduced cell death in R6, increasing survival from ~0.1 % in the absence of the protein inhibitor, to values ranging between 25 to 60 %. Similar percentages of survival were observed in R6ΔssrA when treated with CM, in which cell death levels without protein inhibitor treatment were also remarkably higher (5 to 10 %) than in the wild type. The protective effect of CM increased at longer times and it was extended to other protein inhibitors such as EM. Incubation with both antibiotics increased survival to LVX after
2 h-treatment more than 200-fold (Figure 5D). This means that LVX lethal action in \textit{S. pneumoniae} also requires active protein synthesis, what could explain the less susceptible phenotype of \textit{ΔssrA} cells.

\textbf{Figure 5:} Deficiency of tmRNA protects from chromosome fragmentation mediated by LVX. (A) Analysis of chromosome fragmentation upon LVX treatment by PFGE. Exponentially growing cultures of R6 (\textit{wt}), the R6\textit{ΔssrA} (\textit{ΔssrA}) mutant, the complemented strain containing the pROM-TM (\textit{ΔssrA}\textit{(ssrA\textsuperscript{+})}) and the R6\textit{ΔssrA} containing the empty vector (ROM), were treated with or without 10× MIC of LVX for 30 min and analyzed by PFGE as described in Materials and Methods. (B) Chromosomal fragmentation was estimated by quantification of the compression zone (CZ) relative to the intact chromosomal DNA retained in the well. Each value is the mean of at least three independent experiments and the mean values were statistically compared using Student’s t-test (**\textit{P} < 0.01). (C) Percentage of survival to 1 h treatment of LVX at 5, 10 or 20× MIC of \textit{wt}, \textit{ΔssrA} strains previously incubated with 10 µ/ ml of Chloramphenicol (CM) for 10 min. St stands for the MidRange PFG Marker (Biolabs) with size ranges from 15 to 300 Kb. (D) Percentage of survival along the time to treatment with 5× MIC of \textit{wt} strains previously incubated with 10 µ/ ml of CM or 0.3 µ/ ml of erythromycin (EM) for 10 min. Survival was determined as described in Materials and Methods.
**Discussion**

In this study we provide evidence that *S. pneumoniae* relies on tmRNA for adaptation to a variety of environmental conditions, and that its inactivation reduces the ability of the pneumococcus to cope with several stresses. Our findings showed that tmRNA is not essential for growth in the pneumococcus, although its absence significantly reduced growth rate. Most bacteria require a system to resolve non-stop complexes [8]. On this regard, *S. pneumoniae* is not an exception. The presence of a putative ArfB encoding gene has been predicted in the pneumococcal genome [8] and this is probably the reason why tmRNA is not essential for growth. Moreover, we demonstrated that insertional inactivation of tmRNA did not affect survival to internal oxidative stress induced by paraquat, but reduced the ability to survive to the lethal effect of UV irradiation and had a deleterious effect upon exposure to exogenous H$_2$O$_2$. We also demonstrated that pneumococcal cells lacking tmRNA exhibited higher susceptibility to antibiotics that inhibit protein synthesis or transcription, but not to those targeting cell wall synthesis. The increased sensitivity to protein synthesis inhibitors was rather moderate, similarly to what was previously observed for *E. coli* [21], *Synechocystis* [22] or *Francisella tularensis* [20], whose ssrA null mutants were more sensitive to sublethal concentrations of these drugs. Inhibition of the translation elongation process may cause ribosome stalling, translational inaccuracy and/or read-through, leading to the accumulation of non-stop complexes [24,65,66]. Therefore, the trans-translation system confers the cells with partial resistance to certain antibiotics by dealing with ribosome pausing. In case of rifampicin, the increment in sensitivity exhibited by the ΔssrA mutant was also moderate. A similar sensitive phenotype was observed in *F. tularensis* [20] but no in *E. coli* or *Synechocystis* [21,22], suggesting certain differences among bacteria. This antibiotic inhibits transcription and no ribosome stalling is expected upon rifampicin treatment. However, translation and transcription are known to be coupled and defects in RNA synthesis may ultimately have consequences in translation.
Remarkably, our findings demonstrated that pneumococcal cells lacking tmRNA were more resistant to the four FQs tested (LVX, MOX, CPX and NFX), showing both higher MIC values (2-fold) and higher survival rates (up to 1100-fold). Such resistant phenotype was not observed with penicillin and was not due to the lower growth rate shown by the tmRNA deletion mutant, since increasing the doubling time of wild type at 30ºC had no the same effect. Moreover, this protective phenotype was associated to trans-translation defects and not to side effects of the tmRNA, since similar survival rates were observed in a ΔsmpB strain. This is the first study reporting a higher FQ-resistant phenotype associated to tmRNA inactivation. These results contrast with those previously obtained in E. coli or F. tularensis, where absence of tmRNA was previously reported to either have no effect [20,23,25] or to increase sensitivity [17,67] to nalidixic acid, ofloxacin, NFX or LVX. A possible explanation for the less sensitive phenotype observed in S. pneumoniae could be that depletion of tmRNA might influence membrane permeability, leading to lesser accumulation of the drug inside ΔssrA cells. In fact, absence of tmRNA is expected to prevents tmRNA-mediated tagging of abnormal proteins for degradation and to increases the levels of misfolded proteins [68-70], whose insertion into cell membrane could alter permeability. However, our results demonstrated that cells lacking tmRNA accumulated more EtBr and LVX than the wild type cells. Therefore, cell membrane integrity was indeed altered due to the deletion, but instead of reducing drug accumulation, it led to a significant increase in the levels of intracellular drugs. This means that tmRNA-depleted cells are somehow protected from the lethal effects associated to FQs.

ROS production contributes to FQ-lethality in S. pneumoniae. The intervening pathways between LVX and MOX initial antibiotic-target interaction and ROS formation are now known. LVX treatment inhibits Topo IV increasing fatDCE operon expression, what in turns, increases iron uptake [45]. In the case of MOX, inhibition of both Topo IV and gyrase induce a transcriptomic response that results in an intracellular pyruvate increment that consequently leads to higher levels of H₂O₂ [46]. Consistently, our results demonstrated that the protective effect
against LVX and MOX of \textit{\textDelta ssrA} cells was accompanied by a reduction in ROS accumulation. A similar protective effect was also observed against NFX and CPX, both of which target Topo IV [71], and whose induction of intracellular ROS in \textit{S. pneumoniae} has not been determined. In \textit{E. coli}, these FQs have been shown to act through different pathways, and while NFX-mediated killing involves ROS [40,42], CPX is able to kill bacteria anaerobically [39]. Therefore, the protective effect of tmRNA absence may not be related to specific pathways for each FQ, but to a common feature to all of them. Nevertheless, since MOX addition in pneumococcus triggered a 3-fold reduction in \textit{smpB} transcript levels [46], the involvement of tmRNA in specific regulatory circuits contributing to FQ lethality cannot be ruled out.

Independently of their target and mechanism of action, FQs reversibly trap the topoisomerase on the chromosomal DNA, in a ternary complex in which the DNA is broken [37,38]. Releasing of DNA from these complexes generates deleterious double-stranded breaks [72]. Therefore, no matter the pathway used, the action of all FQs ultimately converges in lethal chromosome fragmentation. On this regard, our findings demonstrated that cells lacking tmRNA showed almost no chromosome fragmentation after LVX treatment, and that the sole tmRNA expression in \textit{trans} is sufficient to completely restore DNA fragmentation to wild type levels. We also demonstrated that addition of CM or EM, which inhibit protein synthesis, drastically increased survival of pneumococci exposed to LVX. These findings confirm that LVX-mediated cell death in pneumococcus also occurs via the protein synthesis-dependent pathway and provide a possible explanation to the less susceptible phenotype of \textit{\textDelta ssrA} cells. The absence of tmRNA is expected to imperil translation due to accumulation of stalled ribosomes in tmRNA depleted cells, which may give cells time to repair damage.

In conclusion, tmRNA has a protective effect under several types of stresses in \textit{S. pneumoniae}. Such protection is likely due to its role in rescuing of stalled ribosomes, helping the cell to recover and proceed with proper translation, and to tagging of abnormal
proteins for degradation. However, upon FQ treatment, tmRNA is paradoxically harmful. The protective effect against FQs associated to tmRNA deficiency is linked to trans-translation and is due to the cumulative effect of two processes: a reduction in ROS production and a decrease in chromosome fragmentation, and translational pausing appear to be the underlying mechanisms. These findings should be taking in consideration in the development of new antibiotics inhibiting trans-translation. Its requirement for viability or virulence in many pathogenic bacteria together with the low expected toxicity in host cells due to its absence in metazoans, has posed this pathway as an attractive antimicrobial target [8,73,74]. However, our results evidence that inactivation of trans-translation may have side effects leading to an undesirable increase resistance to otherwise effective antibiotics. In addition, although not currently used in clinical practice, our results suggest that the combined use of FQs and antibiotics inhibiting protein synthesis might not be recommended and evidence the requirement of further studies on this matter.

References

1. Karzai AW, Susskind MM, Sauer RT. SmpB, a unique RNA-binding protein essential for the peptide-tagging activity of SsrA (tmRNA). EMBO J. 1999; 18: 3793–3799.
2. Karzai AW, Roche ED, Sauer RT. The SsrA-SmpB system for protein tagging, directed degradation and ribosome rescue. Nat. Struct. Biol. 2000; 7: 449–455.
3. Keiler KC, Waller PR, Sauer RT. Role of a peptide tagging system in degradation of proteins synthesized from damaged messenger RNA. Science. 1996; 271: 990–993.
4. Giudice E, Macé K, Gillet R. Trans-translation exposed: understanding the structures and functions of tmRNA-SmpB. Front. Microbiol. 2014; 5: 113.
5. Shimizu Y. Biochemical aspects of bacterial strategies for handling the incomplete translation processes. Front. Microbiol. 2014; 5: 170.
6. Chadani Y, Ono K, Ozawa SI, Takahashi Y, Takai K, et al. Ribosome rescue by Escherichia coli ArfA (YhdL) in the
absence of trans-translation system. Mol. Microbiol. 2010; 78: 796–808.

7. Chadani Y, Ono K, Kutsukake K, Abo T. Escherichia coli YaeJ protein mediates a novel ribosome-rescue pathway distinct from SsrA- and ArfA-mediated pathways. Mol. Microbiol. 2011; 80: 772–785.

8. Keiler KC, Feaga HA. Resolving Nonstop Translation Complexes Is a Matter of Life or Death. J. Bacteriol. 2014; 196: 2123–2130.

9. Schaub RE, Poole SJ, Garza-Sánchez F, Benbow S, Hayes CS. Proteobacterial ArfA peptides are synthesized from non-stop messenger RNAs. J. Biol. Chem. 2012; 287: 29765–29775.

10. Barends S, Zehl M, Bialek S, de Waal E, Traag BA, et al. Transfer-messenger RNA controls the translation of cell-cycle and stress proteins in Streptomyces. EMBO Rep. 2010; 11: 119–125.

11. Julio SM, Heithoff DM, Mahan MJ. ssrA (tmRNA) plays a role in Salmonella enterica serovar Typhimurium pathogenesis. J. Bacteriol. 2000; 182: 1558–1563.

12. Komine Y, Kitabatake M, Yokogawa T, Nishikawa K, Inokuchi H. A tRNA-like structure is present in 10Sa RNA, a small stable RNA from Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 9223–9227.

13. Li X, Yagi M, Morita T, Aiba H. Cleavage of mRNAs and role of tmRNA system under amino acid starvation in Escherichia coli. Mol. Microbiol. 2008; 68: 462–473.

14. Mann B, van Opijnen T, Wang J, Obert C, Wang YD, et al. Control of virulence by small RNAs in Streptococcus pneumoniae. PLoS Pathog. 2012; 8: e1002788.

15. Mu X, Huan H, Xu H, Gao Q, Xiong L, et al. The transfer-messenger RNA-small protein B system plays a role in avian pathogenic Escherichia coli pathogenicity. J. Bacteriol. 2013; 195: 5064–5071.

16. Muto A, Fujihara A, Ito KI, Matsuno J, Ushida C, et al. Requirement of transfer-messenger RNA for the growth of Bacillus subtilis under stresses. Genes Cells Devoted Mol. Cell. Mech. 2000; 5: 627–635.
17. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M, et al. Phenotypic landscape of a bacterial cell. Cell. 2011; 144: 143–156.
18. Oh BK, Apirion D. 10Sa RNA, a small stable RNA of Escherichia coli, is functional. Mol. Gen. Genet. 1991; 229: 52–56.
19. Okan NA, Bliska JB, Karzai AW. A Role for the SmpB-SsrA system in Yersinia pseudotuberculosis pathogenesis. PLoS Pathog. 2006; 2: e6.
20. Svetlanov A, Puri N, Mena P, Koller A, Karzai AW. Francisella tularensis tmRNA system mutants are vulnerable to stress, avirulent in mice, and provide effective immune protection. Mol. Microbiol. 2012; 85: 122–141.
21. Abo T, Ueda K, Sunohara T, Ogawa K, Aiba H. SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells Devoted Mol. Cell. Mech. 2002; 7: 629–638.
22. de la Cruz J, Abo A. Increased sensitivity to protein synthesis inhibitors in cells lacking tmRNA. RNA N. Y. N. 2001; 7: 1708–1716.
23. Luidalepp H, Hallier M, Felden B, Tenson T. tmRNA decreases the bactericidal activity of aminoglycosides and the susceptibility to inhibitors of cell wall synthesis. RNA Biol. 2005; 2: 70–74.
24. Vioque A, Cruz J de la. Trans-translation and protein synthesis inhibitors. FEMS Microbiol. Lett. 2003; 218: 9–14.
25. Abo T, Inada T, Ogawa K, Aiba H. SsrA-mediated tagging and proteolysis of LacI and its role in the regulation of lac operon. EMBO J. 2000; 19: 3762–3769.
26. Christensen SK, Gerdes K. ReLE toxins from bacteria and Archaea cleave mRNAs on translating ribosomes, which are rescued by tmRNA. Mol. Microbiol. 2003; 48: 1389–1400.
27. Christensen SK, Pedersen K, Hansen FG, Gerdes K. Toxin-antitoxin loci as stress-response-elements: ChpAK/MazF and ChpBK cleave translated RNAs and are counteracted by tmRNA. J. Mol. Biol. 2003; 332: 809–819.
28. Keiler KC. Biology of trans-translation. Annu. Rev. Microbiol. 2008; 62: 133–151.
29. Keiler KC, Shapiro L. tmRNA Is Required for Correct Timing of DNA Replication in Caulobacter crescentus. J. Bacteriol. 2003; 185: 573–580.
30. Kobayashi K, Kuwana R, Takamatsu H. kinA mRNA is missing a stop codon in the undomesticated Bacillus subtilis strain ATCC 6051. Microbiol. Read. Engl. 2008; 154: 54–63.
31. Ranquet C, Gottesman S. Translational regulation of the Escherichia coli stress factor RpoS: a role for SsrA and Lon. J. Bacteriol. 2007; 189: 4872–4879.
32. WHO. Pneumococcal conjugate vaccine for childhood immunization--WHO position paper. Relevé Épidémiologique Hebd. Sect. Hygiène Secrétariat Société Nations Wkly. Epidemiol. Rec. Health Sect. Secr. Leag. Nations. 2007; 82: 93–104.
33. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009; 374: 893–902.
34. Jacobs MR, Felmingham D, Appelbaum PC, Grünéberg RN, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.
35. Sahm DF, Karlowsky JA, Kelly LJ, Critchley IA, Jones ME, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 2001; 45: 1037–1042.
36. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 2001; 70: 369–413.
37. Chen CR, Malik M, Snyder M, Drlica K. DNA Gyrase and Topoisomerase IV on the Bacterial Chromosome: Quinolone-induced DNA Cleavage. J. Mol. Biol. 1996; 258: 627–637.
38. Malik M, Zhao X, Drlica K. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 2006; 61: 810–825.
39. Malik M, Hussain S, Drlica K. Effect of anaerobic growth on quinolone lethality with Escherichia coli. Antimicrob. Agents Chemother. 2007; 51: 28–34.
40. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol. Syst. Biol. 2007; 3: 91.
41. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, et al. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc. Natl. Acad. Sci. U. S. A. 2014; 111: E2100-2109.
42. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics. Cell. 2007; 130: 797–810.
43. Wang X, Zhao X. Contribution of oxidative damage to antimicrobial lethality. Antimicrob. Agents Chemother. 2009; 53: 1395–1402.
44. Wang X, Zhao X, Malik M, Drlica K. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J. Antimicrob. Chemother. 2010; 65: 520–524.
45. Ferrándiz MJ, de la Campa AG. The fluoroquinolone levofloxacin triggers the transcriptional activation of iron transport genes that contribute to cell death in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2014; 58: 247–257.
46. Ferrándiz MJ, Martín-Galiano AJ, Arnanz C, Zimmerman T, Campa AG de la. Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2016; 60: 409–417.
47. Acebo P, Martin-Galiano AJ, Navarro S, Zaballos A, Amblar M. Identification of 88 regulatory small RNAs in the TIGR4 strain of the human pathogen Streptococcus pneumoniae. RNA N. Y. N. 2012; 18: 530–546.
48. Kumar R, Shah P, Swiatlo E, Burgess SC, Lawrence ML, et al. Identification of novel non-coding small RNAs from Streptococcus pneumoniae TIGR4 using high-resolution genome tiling arrays. BMC Genomics. 2010; 11: 350.
49. Wilton J, Acebo P, Herranz C, Gómez A, Amblar M. Small regulatory RNAs in Streptococcus pneumoniae: discovery and biological functions. Front. Genet. 2015; 6: 126.
50. Moreira RN, Domingues S, Viegas SC, Amblar M, Arraiano CM. Synergies between RNA degradation and trans-
translation in Streptococcus pneumoniae: cross regulation and co-transcription of RNase R and SmpB. BMC Microbiol. 2012; 12: 268.

51. Richards J, Mehta P, Karzai AW. RNase R degrades non-stop mRNAs selectively in an SmpB-tmRNA-dependent manner. Mol. Microbiol. 2006; 62: 1700–1712.

52. Lacks SA, Lopez P, Greenberg B, Espinosa M. Identification and analysis of genes for tetracycline resistance and replication functions in the broad-host-range plasmid pLS1. J. Mol. Biol. 1986; 192: 753–765.

53. Ruiz-Maso JA, Lopez-Aguilar C, Nieto C, Sanz M, Buron P, et al. Construction of a plasmid vector based on the pMV158 replicon for cloning and inducible gene expression in Streptococcus pneumoniae. Plasmid. 2012; 67: 53–59.

54. Song JH, Ko KS, Lee JY, Baek JY, Oh WS, et al. Identification of essential genes in Streptococcus pneumoniae by allelic replacement mutagenesis. Mol. Cells. 2005; 19: 365–374.

55. Sung CK, Li H, Claverys JP, Morrison DA. An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl. Environ. Microbiol. 2001; 67: 5190–5196.

56. Pericone CD, Park S, Imlay JA, Weiser JN. Factors Contributing to Hydrogen Peroxide Resistance in Streptococcus pneumoniae Include Pyruvate Oxidase (SpxB) and Avoidance of the Toxic Effects of the Fenton Reaction. J. Bacteriol. 2003; 185: 6815–6825.

57. Andisi VF, Hinojosa CA, de Jong A, Kuipers OP, Orihuela CJ, et al. Pneumococcal gene complex involved in resistance to extracellular oxidative stress. Infect. Immun. 2012; 80: 1037–1049.

58. Halpern D, Gruss A, Claverys JP, El-Karoui M. rexAB mutants in Streptococcus pneumoniae. Microbiol. Read. Engl. 2004; 150: 2409–2414.

59. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100-S18Wayne, Pennsylvania. Clinical-and-Laboratory-Standards-Institute. 2008.
60. Pérez-Boto D, Acebo P, García-Peña FJ, Abad JC, Echeita MA, et al. Isolation of a point mutation associated with altered expression of the CmeABC efflux pump in a multidrug-resistant Campylobacter jejuni population of poultry origin. J. Glob. Antimicrob. Resist. 2015; 3: 115–122.
61. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, et al. Quinolone Efflux Pumps Play a Central Role in Emergence of Fluoroquinolone Resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2006; 50: 310–317.
62. Piddock LJV, Johnson MM. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2002; 46: 813–820.
63. Deitz WH, Cook TM, Goss WA. Mechanism of Action of Nalidixic Acid on Escherichia coli III. Conditions Required for Lethality. J. Bacteriol. 1966; 91: 768–773.
64. Ferrándiz MJ, Oteo J, Aracil B, Gómez-Garcés JL, De La Campa AG. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci. Antimicrob. Agents Chemother. 1999; 43: 2520–2523.
65. Thompson J, O’Connor M, Mills JA, Dahlberg AE. The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in Vivo. J. Mol. Biol. 2002; 322: 273–279.
66. Thompson J, Pratt CA, Dahlberg AE. Effects of a Number of Classes of 50S Inhibitors on Stop Codon Readthrough during Protein Synthesis. Antimicrob. Agents Chemother. 2004; 48: 4889–4891.
67. Li J, Ji L, Shi W, Xie J, Zhang Y. Trans-translation mediates tolerance to multiple antibiotics and stresses in Escherichia coli. J. Antimicrob. Chemother. 2013; 68: 2477–2481.
68. Choy JS, Aung LL, Karzai AW. Lon protease degrades transfer-messenger RNA-tagged proteins. J. Bacteriol. 2007; 189: 6564–6571.
69. Gottesman S, Roche E, Zhou Y, Sauer RT. The ClpXP and ClpAP proteases degrade proteins with carboxy-terminal peptide tails added by the SsrA-tagging system. Genes Dev. 1998; 12: 1338–1347.
70. Herman C, Thévenet D, Boulou P, Walker GC, D’Ari R. Degradation of carboxy-terminal-tagged cytoplasmic proteins
by the Escherichia coli protease HflB (FtsH). Genes Dev. 1998; 12: 1348–1355.

71. Muñoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 1996; 40: 2252–2257.

72. Drlica K, Malik M, Kerns RJ, Zhao X. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 2008; 52: 385–392.

73. Keiler KC, Alumasa JN. The potential of trans-translation inhibitors as antibiotics. Future Microbiol. 2013; 8: 1235–1237.

74. Ramadoss NS, Alumasa JN, Cheng L, Wang Y, Li S, et al. Small molecule inhibitors of trans-translation have broad-spectrum antibiotic activity. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 10282–10287.

75. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001; 293: 498–506.